Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S016 - Psoriasis

Sunday, July 29; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Discuss psoriasis comorbidities
  • Treat adult and pediatric psoriasis and learn about new therapeutic options
  • Manage psoriasis patients with special considerations

Description

During this session, we will review existing therapies and update efficacy and safety profiles of the biologics & oral agents currently available. We will review the emerging therapies for psoriasis & Psoriatic arthritis. We will discuss the treatment of psoriasis in special populations such as pediatric and pregnant patients as well as those with infections such as Hepatitis C and HIV.

Disclosures

  • Boh, Erin E., MD, PhD: AbbVie – I(Grants/Research Funding), SP(H); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); Incyte Corporation – I(Grants/Research Funding); Janssen-Ortho Inc. – I(Grants/Research Funding), SP(H); Lilly ICOS LLC – A(H); National Psoriasis Foundation – A(NC); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding), SP(H); Regeneron – Speaker/Faculty Education(H); Sanofi – Speaker/Faculty Education(H); Soligenix, Inc – I(Grants/Research Funding);
  • Green, Lawrence J., MD: AbbVie – SP(H); Allergan, Inc. – C(H), Speaker/Faculty Education(H); Amgen – SP(H); Brickell Biotech, Inc. – I(Grants/Research Funding); Celgene Corporation – SP(H); Dermira – I(Grants/Research Funding); Leo Pharma Inc. – SP(H); Merz Aesthetics – A(H), I(Grants/Research Funding); Novartis – C(H), I(Grants/Research Funding), SP(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – C(H), I(Grants/Research Funding); ZO Skin Health, Inc. – C(H);
  • Jackson, J. Mark, MD: AbbVie – C(H), I(Grants/Research Funding); Accuitis, Inc – C(Fees), C(SO); Amgen – C(H), I(Grants/Research Funding); Celgene Corporation – C(Fees), I(Grants/Research Funding); Galderma Laboratories, L.P. – C(H), I(Grants/Research Funding); Genentech, Inc. – C(H); Janssen-Ortho Inc. – A(H), I(Grants/Research Funding); Johnson & Johnson Pharmaceutical Research & Development – C(H), I(Grants/Research Funding); Lilly ICOS LLC – C(H), I(Grants/Research Funding); Medimetriks Pharmaceuticals, Inc. – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Promius Pharmaceuticals – C(H); Ralexar Therapeutics, Inc – C(Fees), C(SO); TopMD – A(SO); Valeant Pharmaceuticals North America LLC – C(H);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Aqua – C(H); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Boehringer Ingelheim – C(H); Celgene Corporation – I(Grants/Research Funding); Corrona, Inc. – O(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Janssen Research & Development, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); Medimmune – I(Grants/Research Funding); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding); Vidac Pharma – I(Grants/Research Funding);
  • Murina, Andrea Tesvich, MD: AbbVie – SP(H); Celgene – A(H); Celgene Corporation – SP(H); Novartis – SP(H); Regeneron – O(Grants/Research Funding);
Schedule
Sunday, July 29
9:00 AM
Dr. Murina / Psoriasis comorbidities and special considerations
9:30 AM
Dr. Boh / Biologic treatments for psoriasis: TNF inhibitors
10:00 AM
All faculty / Questions
10:15 AM
Dr. Jackson / Biologic treatments for psoriasis: IL-17 and IL-23 inhibitors
10:45 AM
All faculty / Questions
11:00 AM
Dr. Green / Oral agents for psoriasis
11:30 AM
Dr. Lebwohl / Psoriasis treatments in the pipeline
Event Details
  • Date
    Sunday, July 29
  • Time
    9:00 AM - 12:00 PM
  • Location
    Regency Ballroom B
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Erin E. Boh, MD, PhD, FAAD
  • Andrea Tesvich Murina, MD, FAAD
Speakers
  • J. Mark Jackson, MD, FAAD
  • Lawrence J. Green, MD, FAAD
  • Mark Lebwohl, MD, FAAD - Handout 1, Handout 2